What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Disease
His scientific interests lie mostly in Psoriasis, Immunology, Internal medicine, Severity of illness and Dermatology.
His Psoriasis study combines topics in areas such as Genetics, Genome-wide association study and Surgery.
As a member of one scientific family, Ulrich Mrowietz mostly works in the field of Immunology, focusing on Receptor and, on occasion, Transcription factor, Downregulation and upregulation and Aryl hydrocarbon receptor.
His Internal medicine research focuses on Placebo and how it connects with Apremilast.
His Severity of illness research integrates issues from Quality of life and Intensive care medicine.
His studies deal with areas such as Etanercept and MEDLINE as well as Dermatology.
His most cited work include:
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity (644 citations)
- European S3-guidelines on the systemic treatment of psoriasis vulgaris (526 citations)
- Definition of treatment goals for moderate to severe psoriasis: a European consensus (482 citations)
What are the main themes of his work throughout his whole career to date?
Ulrich Mrowietz mostly deals with Psoriasis, Dermatology, Internal medicine, Immunology and Psoriasis Area and Severity Index.
In his research on the topic of Psoriasis, Comorbidity is strongly related with Disease.
His study in Dermatology is interdisciplinary in nature, drawing from both Infliximab and MEDLINE.
Ulrich Mrowietz frequently studies issues relating to Placebo and Internal medicine.
His Chemotaxis research extends to the thematically linked field of Immunology.
His Dermatology Life Quality Index research is under the purview of Quality of life.
He most often published in these fields:
- Psoriasis (57.73%)
- Dermatology (27.11%)
- Internal medicine (20.70%)
What were the highlights of his more recent work (between 2017-2021)?
- Psoriasis (57.73%)
- Internal medicine (20.70%)
- Dermatology (27.11%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Psoriasis, Internal medicine, Dermatology, Psoriasis Area and Severity Index and Secukinumab.
His work carried out in the field of Psoriasis brings together such families of science as Quality of life, Disease and Family medicine.
His work on Inflammatory bowel disease is typically connected to Systemic therapy as part of general Disease study, connecting several disciplines of science.
He usually deals with Internal medicine and limits it to topics linked to Placebo and Clinical endpoint and Nail.
His research integrates issues of Plaque psoriasis and Clinical trial in his study of Psoriasis Area and Severity Index.
He works mostly in the field of Secukinumab, limiting it down to topics relating to Ustekinumab and, in certain cases, Acitretin, Apremilast, Etanercept and Intensive care medicine.
Between 2017 and 2021, his most popular works were:
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study) (85 citations)
- S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment (57 citations)
- The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects. (43 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Disease
The scientist’s investigation covers issues in Psoriasis, Internal medicine, Dermatology, Psoriasis Area and Severity Index and Secukinumab.
The study incorporates disciplines such as Body surface area, Severity of illness and Disease in addition to Psoriasis.
His Disease research is multidisciplinary, relying on both Interleukin and Metabolic syndrome.
His work on Papulopustular rosacea as part of general Dermatology research is frequently linked to Systemic therapy, thereby connecting diverse disciplines of science.
His study focuses on the intersection of Psoriasis Area and Severity Index and fields such as Plaque psoriasis with connections in the field of Methotrexate and Fumaric Acid Esters.
His Secukinumab research includes themes of Infliximab, Ustekinumab, Apremilast, Placebo and Acitretin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
